NICE recommended that the country's National Health Service not prescribe Polivy.
News & Analysis: Roche Holding Ltd. (ADR)
It's another win for the promising treatment.
Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.
If candidate drug risdiplam is approved, it could be a major competitor to treatments already developed by Biogen and Novartis.
Some of the biopharma industry's biggest names are taking important steps to combat the world's latest public health emergency.
Its newer drugs are more than making up for the waning sales of older medications.
The number of gene therapy candidates is expected to skyrocket in the near future.
It's not the first bladder-cancer related setback for the drug, but it surprised industry experts nonetheless.
Strong clinical results are bolstering the odds that risdiplam will receive FDA approval this year.
The two companies aim to make significant advances in cancer research and make genomics accessible to more patients.